Ono Pharmaceutical, China Chemical & Pharmaceutical deal

Ono granted CCPC exclusive, Taiwanese rights to develop and commercialize limaprost alfadex to treat lumbar spinal canal stenosis. CCPC is responsible for marketing approval in Taiwan, and Ono is eligible for undisclosed royalties. Ono declined to disclose financial terms, and CCPC could not be reached. ...